Segmentation by type distinguishes the influenza virus vector vaccine market into four technical sub‑categories: Replication‑competent vectors, Replication‑deficient vectors, Chimeric vectors, and Reassortant vectors. Replication‑competent vectors, which retain the ability to undergo limited replication in host cells, contribute the largest share of R&D budgets due to their robust antigen expression, though they face stricter safety scrutiny that can limit market penetration. Replication‑deficient vectors, engineered to lack essential genes for viral propagation, occupy a growing niche because they balance immunogenicity with an improved safety profile, attracting both public‑sector and private investment. Chimeric vectors combine influenza surface proteins with heterologous viral backbones to broaden immune coverage, a strategy gaining traction in pandemic preparedness scenarios. Reassortant vectors, generated through gene segment exchange, are primarily used for seasonal vaccine updates, leveraging existing manufacturing platforms. Each type adds distinct value to the market by affecting manufacturing complexity, regulatory timelines, and ultimately, the total addressable market.